Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura

Who is this study for? Patients with migraine aura
What treatments are being studied? Amiloride
Status: Recruiting
Location: See all (5) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Recent data suggest involvement of Acid-Sensing Ion Channel channels in the pathophysiology of migraine making these channels a therapeutic target of migraine disease. The implication of Acid-Sensing Ion Channels is discussed through Acid-Sensing Ion Channel-1 which is the most expressed Acid-Sensing Ion Channel channel subtype in the central nervous system. In a mouse model, cortical spreading depression is inhibited by different Acid-Sensing Ion Channel blockers including amiloride which is a non-selective blocker of the Acid-Sensing Ion Channel-1 channel. From a translational perspective, an efficacy of amiloride on a series of migraine patients suffering from severe aura in open conditions. The APAM study is a proof-of-concept study that aims to evaluate the effect of amiloride in the prophylaxis of migraine with aura. This is a randomized crossover study versus placebo conducted in 3 French headache centers.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Diagnosis of migraine with aura code

• At least 1 aura with aura per month in the 3 months prior to inclusion

• No prophylactic antimigraine treatment for at least 1 month prior to inclusion

• For women of childbearing age, use of a reliable contraceptive method at least 3 months before and 1 month after the study

• Signature of written informed consent

• Patient affiliated with Social Security

Locations
Other Locations
France
Hôpital Pierre Wertheimer
NOT_YET_RECRUITING
Bron
CHU Gabriel Montpied
NOT_YET_RECRUITING
Clermont-ferrand
AP-HM
RECRUITING
Marly
CHU de Montpellier
RECRUITING
Montpellier
CHU de NICE
RECRUITING
Nice
Contact Information
Primary
Michel LANTERI-MINET, Dr
lanteri-minet.m@chu-nice.fr
04 92 03 76 46
Backup
sylvie ROMETTINO
romettino.s@chu-nice.fr
Time Frame
Start Date: 2020-08-11
Estimated Completion Date: 2025-12
Participants
Target number of participants: 40
Treatments
Other: placebo-amiloride
Patients will be treated for 12 weeks with placebo and then after a 4 week wash-out period, will be treated for 12 weeks with amiloride.
Other: amiloride -placebo
Patients will be treated for 12 weeks with amiloride and then after a 4 week wash-out period, will be treated for 12 weeks with placebo.
Authors
Emilie PIQUET
Sponsors
Leads: Centre Hospitalier Universitaire de Nice

This content was sourced from clinicaltrials.gov